株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

間質性膀胱炎 (膀胱痛症候群) :パイプライン製品の分析

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 213127
出版日 ページ情報 英文 90 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.08円で換算しております。
Back to Top
間質性膀胱炎 (膀胱痛症候群) :パイプライン製品の分析 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2017
出版日: 2017年09月19日 ページ情報: 英文 90 Pages
概要

間質性膀胱炎は、膀胱痛症候群とも呼ばれる慢性疾患で、膀胱圧、膀胱痛、骨盤痛など、軽度の不快感から激痛まで含まれます。膀胱容量の低下、性交痛、慢性骨盤痛、頻尿、尿意切迫感などの症状が見られます。危険因子は、年齢、性別、慢性疼痛性障害 (過敏性腸症候群、線維筋痛症など) です。治療には、非ステロイド性抗炎症薬、抗鬱薬、抗ヒスタミン薬などが含まれます。

当レポートでは、間質性膀胱炎 (膀胱痛症候群) に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

間質性膀胱炎 (膀胱痛症候群) の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

間質性膀胱炎 (膀胱痛症候群):企業で開発中の治療薬

間質性膀胱炎 (膀胱痛症候群):大学/機関で研究中の治療薬

間質性膀胱炎 (膀胱痛症候群):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

間質性膀胱炎 (膀胱痛症候群):企業で開発中の製品

間質性膀胱炎 (膀胱痛症候群):大学/機関で研究中の製品

間質性膀胱炎 (膀胱痛症候群) の治療薬開発に従事している企業

  • Afferent Pharmaceuticals, Inc.
  • Allergan Plc
  • Aquinox Pharmaceuticals Inc.
  • アステラス製薬
  • Kytogenics Pharmaceuticals, Inc.
  • Lipella Pharmaceuticals, Inc.
  • MediPost Co., Ltd.
  • Qu Biologics Inc.
  • UCB S.A.
  • Urigen Pharmaceuticals, Inc.
  • UroGen Pharmaceuticals, Ltd.

間質性膀胱炎 (膀胱痛症候群):治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

間質性膀胱炎 (膀胱痛症候群):最近のパイプライン動向

間質性膀胱炎 (膀胱痛症候群):休止中のプロジェクト

間質性膀胱炎 (膀胱痛症候群):開発が中止された製品

間質性膀胱炎 (膀胱痛症候群):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9724IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2017, provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) pipeline landscape.

Interstitial cystitis also called painful bladder syndrome is a chronic condition in which person experience bladder pressure, bladder pain and sometimes pelvic pain, ranging from mild discomfort to severe pain. Symptoms include decreased bladder capacity, painful sexual intercourse, chronic pelvic pain and a persistent, urgent need to urinate. Risk factors include age, gender and chronic pain disorder, such as irritable bowel syndrome or fibromyalgia. Treatment includes non-steroidal anti-inflammatory drug, antidepressants and antihistamines.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 3, 6, 9 and 1 respectively.

Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interstitial Cystitis (Painful Bladder Syndrome) - Overview
    • Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development
    • Allergan Plc
    • Aquinox Pharmaceuticals Inc
    • Astellas Pharma Inc
    • BELLUS Health Inc
    • Idera Pharmaceuticals Inc
    • Kyorin Pharmaceutical Co Ltd
    • Kytogenics Pharmaceuticals Inc
    • Lipella Pharmaceuticals Inc
    • Merck & Co Inc
    • UCB SA
    • Urigen Pharmaceuticals Inc
    • Xigen SA
  • Interstitial Cystitis (Painful Bladder Syndrome) - Drug Profiles
    • (heparin + lidocaine hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALV-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit NLRP3 for Inflammatory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-6294 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLU-5937 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brimapitide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • certolizumab pegol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dimethyl sulfoxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • F-16357 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gefapixant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GM-0111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ICE-3682 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lidocaine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LP-08 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mesalamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • onabotulinumtoxinA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pentosan polysulfate sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rosiptor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • URG-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects
  • Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products
  • Interstitial Cystitis (Painful Bladder Syndrome) - Product Development Milestones
    • Featured News & Press Releases
      • Aug 28, 2017: Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome
      • Oct 03, 2016: Aquinox Announces Appointment of Dr. Barbara Troupin as Chief Medical Officer
      • Sep 27, 2016: Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society
      • Sep 06, 2016: Aquinox Pharmaceuticals Initiates Patient Dosing in LEADERSHIP 301 Phase 3 Clinical Trial of AQX-1125 in Interstitial Cystitis/Bladder Pain Syndrome
      • May 25, 2016: Aquinox Announces Executive Appointments
      • May 10, 2016: Aquinox Pharmaceuticals Announces First Quarter 2016 Financial Results
      • May 03, 2016: Allergan Presents New Data on LiRIS 400 mg at the American Urological Association Meeting in San Diego
      • Jan 11, 2016: Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA
      • Dec 22, 2015: Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration
      • Sep 18, 2015: Aquinox Presents at 2015 International Society for the Study of BPS Conference
      • Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis
      • Aug 25, 2015: LEADERSHIP Results Accepted for Podium Presentation at the 2015 Annual Meeting of the International Society for the Study of BPS
      • Aug 06, 2015: Aquinox Pharmaceuticals Announces Positive Results From Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC
      • Jul 28, 2015: Aquinox Pharmaceuticals to Provide Update on Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC
      • Jun 25, 2015: Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Allergan Plc, H2 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Aquinox Pharmaceuticals Inc, H2 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Astellas Pharma Inc, H2 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by BELLUS Health Inc, H2 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Idera Pharmaceuticals Inc, H2 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kytogenics Pharmaceuticals Inc, H2 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Lipella Pharmaceuticals Inc, H2 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Merck & Co Inc, H2 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by UCB SA, H2 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Urigen Pharmaceuticals Inc, H2 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Xigen SA, H2 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects, H2 2017
  • Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top